Economic Evaluation of Nivolumab (NIVO) Plus Ipilimumab (IPI) Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.248
https://www.valueinhealthjournal.com/article/S1098-3015(17)30582-X/fulltext
Title :
Economic Evaluation of Nivolumab (NIVO) Plus Ipilimumab (IPI) Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30582-X&doi=10.1016/j.jval.2017.08.248
First page :
A441
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
223